Strategy
Faron’s strategy reflects a significant demand for novel therapies to manage symptoms and improve outcomes in challenging cases of hematologic cancers and solid tumors.
Key elements of Faron’s strategy
Become revenue generating with data from MDS
- Partnership(s) and first approvals
Expand by generating Proof of Concept Phase II data in new indications
- Both in blood cancers and solid tumors
New Phase II studies will be primarily ran using funds obtained through deals and partnerships
- A tiered approach until resources enable parallel development in multiple indications and settings at the same time
New Phase II studies will commence depending on available resources, clinical importance and market opportunity, i.e. non-competitive areas with clear unmet need
Value creation opportunity with full Phase II read-outs (response rate, duration of response and survival), regulatory interactions, partnering and combination data with anti-PD-1
- Phase II enrollment completed by Jan 2025
- End of Q1 2025 full Phase 2 response rate readout
- End of Q2 2025 FDA EOP2 meeting and Breakthrough Designation possibility
- End of Q3 2025 Phase 2 duration of response and survival data
- Q4 2025 Regulatory feedback on accelerated approval possibility
- Q4 2025 First combination data with anti-PD1